Preliminary Data in Faridoxorubicin Phase 1b Trial
Avacta Group plc will announce preliminary clinical data for its Faridoxorubicin Phase 1b trial in salivary gland cancer on December 17, 2025, with a presentation available via the Investor Meet Platform at 10:00 AM GMT. This announcement pertains to the company's development of next-generation peptide drug conjugates (PDCs) designed to target anti-tumor payloads directly to tumors, aiming to reduce toxicity and improve efficacy.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
LONDON and PHILADELPHIA - December 8, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, expects to announce initial Faridoxorubicin Phase 1b data in the salivary gland cancer indication on December 17, 2025. A presentation will be made available via the Investor Meet Platform on December 17, 2025, at 10:00 AM GMT. The link to view the presentation is below. Investors can register for the webinar and submit questions through the platform link below at any time before the presentation.
| About pre | CISION® |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.